Oncolytics Biotech ONCY 深 沪
已收盘 10-02 16:00:00 美东时间
0.631
-0.010
-1.59%
华盛通- 最 高0.6521
- 今 开0.6521
- 成交量 61.18万股
- 最 低 0.6211
- 昨 收 0.6412
- 总市值 8045.91万
- 52周最高 1.32
- 市盈率 静 --
- 换手率 0.48%
- 52周最低 0.6211
- 委 比 -95.52%
- 总股本 1.28亿
- 历史最高 6.037
- 量 比 0.71
- 振 幅 4.83%
- 历史最低 0.3258
- 每 手 1
- 风险率 0.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oncolytics Biotech Highlights Pelareorep’s Tumor-Activating Potential
Oncolytics Biotech ( ($ONCY) ) has shared an announcement. On September 29, 202...
09-29 22:00
Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to change an immunologically inactive liver cancer tum...
09-29 21:33
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the com...
09-28 20:00
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Oncolytics Biotech announced progress in its REO 033 clinical trial evaluating pelareorep in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer. Nearly all planned clinical sites for Part A have been activated, with multiple patients enrolled. The company expects to report interim data by year-end 2026 and has aligned with the FDA on a potential accelerated approval path based on objective response rate and full approval b...
09-28 13:30
Oncolytics Biotech Reports Positive Pelareorep Preclinical Results
The latest announcement is out from Oncolytics Biotech ( ($ONCY) ). On Septembe...
09-10 20:48
Oncolytics Biotech Announces Pelareorep Lowered Tumor Growth Compared To Control During Initial Treatment Period
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the initial...
09-10 20:16
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price target from $10 to $5.
08-19 20:37
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Oncolytics Biotech received FDA feedback supporting the potential expansion of its REO 033 study into a pivotal Part B, which could enable accelerated approval based on objective response rate and progression-free survival for full approval. The FDA suggested an End-of-Phase meeting to finalize the registration program, prompting the company to cancel its planned Type D meeting. The feedback aligns with the proposed study design and development p...
08-18 13:00
Oncolytics Biotech(ONCY.US)获FDA快速通道资格 将迎关键监管会议
经济观察网 Oncolytics Biotech Inc.（ONCY）旗下pelareorep相关研发及商业化布局推进，获FDA快速通道资格及新专利，后续将召开...
07-31 21:56
